Lario Therapeutics (‘Lario TX’, or ‘the Company’), is a biopharmaceutical company that develops first-in-class precision medicine. Targeting disease-modifying treatments for severe neurological disorders, received the CDLK5 Forum Award for “Company Making a Difference 2023 Pre-clinical” from the Loulou Foundation at the annual CDKL5 Forum. The award recognizes the development of a validated, precision medicine approach to genetic epilepsy. Lario Tx’s first-in-class, orally active, CNS-penetrating CaV2.3 ion channel inhibitors hold promise as novel anti-seizure therapeutics for multiple epilepsy subtypes, including CDKL5 deficiency disorders.
The CDKL5 Forum, established by the Loulou Foundation, is the largest annual conference on CDKL5 deficiency disorders (CDD). CDD is the most common form of genetic developmental epileptic encephalopathy (DEE), affecting approximately 1:40K live births. Due to loss of function of the CDKL5 protein kinase expressed in the brain, the rare neurological disease leads to seizures, developmental delays and severe intellectual disability in most patients. The leading hypothesis is that CDKL5 regulates CaV2.3 channel function, which may explain the devastating seizure characteristics of the disorder. CaV2.3 is now being investigated as a key target for CDD and CaV2.3 inhibitors hold great promise as a precision medicine approach.
Henning Steinhagen, PhD, co-founder and CEO of Lario Therapeutics commented: “We are honored and thank the Loulou Foundation for recognizing our approach which we hope will have a positive impact on patients with CDKL5 deficiency disorders. Our target, CaV2.3, represents one of the few newly validated precision medicine approaches in neurology and has significant potential in other neurological disorders, including severe epilepsy and Parkinson’s disease. We plan to rapidly advance our therapeutic programs toward IND and are supported by our partners and investors.”
Dan Lavery, Ph.D., CSO of the Lulu Foundation, said: “The CDKL5 Forum ‘Company Making a Difference Award (Pre-Clinical)’ recognizes the industry partner who has demonstrated the greatest commitment to pre-clinical therapeutic development for CDD over the past year. At the CDKL5 Forum 2023, the Loulou Foundation is pleased to recognize the team at Lario Therapeutics, a dynamic team of experienced scientists developing a novel therapeutic approach for our patients living with CDD. The Lario team has shown amazing dedication and engagement with our community, and we are delighted to have them join our CDKL5 community as they advance their CaV2.3 pre-clinical development program.“ Anna Mingorens, PhD, CDO of the Lulu Foundation, added: “A major discovery about CDD last year was that CaV2.3 is a key target for CDKL5, which is deregulated in the absence of CDKL5. This means that CaV2.3 inhibitors hold promise as a precision medicine approach to treat CDD“
Sinclair Dunlop, investment director at Lario Therapeutics, said: “This is an exciting time for Lario Therapeutics, and Epidarex Capital is pleased to support Henning and the team at this important juncture. The company’s vision to develop novel disease-modifying precision medicines for the management of serious neurological disorders places Lario in a unique position to address potentially transformative, unmet clinical needs. and represents a significant market opportunity.”
Lario Tx was founded in 2021 as a spin-out from Epidarex Exeed (epidarex-exeed.com), Epidarex Capital’s therapeutic discovery engine, with seed investment from Epidarex Capital and Axxam that shifted its participation in Golgi Neuroscience. The company is growing fast and has a highly motivated and experienced team led by co-founder and CEO Dr. Henning Steinhagen.
For more information on Lario Therapeutics please visit lariotx.com.